Literature DB >> 19840253

Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis.

Kalliopi Zachou1, Cihan Yurdaydin, Uta Drebber, George N Dalekos, Andreas Erhardt, Yilmaz Cakaloglu, Halil Degertekin, Selim Gurel, Stefan Zeuzem, Hakan Bozkaya, Verena Schlaphoff, Hans P Dienes, Thomas C Bock, Michael P Manns, Heiner Wedemeyer.   

Abstract

UNLABELLED: Abstract Background: Hepatitis delta virus (HDV) causes severe liver disease. AIMS: To investigate the quantitative HDV-RNA, HBsAg and hepatitis B virus (HBV)DNA levels in correlation to histological, biochemical and demographical parameters in patients with chronic HDV infection as similar data in a large series of HDV patients are missing.
METHODS: Eighty HDV patients were recruited in Germany, Turkey and Greece; quantitative determination of HDV-RNA, HBsAg and HBV-DNA was performed by real-time polymerase chain reaction, the Architect HBsAg assay and Cobas TaqMan HBV test respectively.
RESULTS: All patients were infected with HDV-genotype 1. Thirty-five patients (48%) had significant fibrosis (Ishak 3-4) and 15 (20.5%) had cirrhosis. HDV viraemia ranged from 1.1 x 10(3) to 8.4 x 10(7) copies/ml with 60% of patients showing HDV-RNA levels above 10(5) copies/ml accompanied by low HBV viraemia (<10(5) copies/ml). However, HDV-RNA and HBV-DNA levels showed no direct inverse correlation. HDV-RNA correlated positively with HBsAg and negatively with age. HBsAg correlated negatively with age and positively with histological grading. Only gamma-glutamyltranspeptidase was independently associated with cirrhosis (P=0.032), while no biochemical parameter was associated with grading.
CONCLUSIONS: (i) HBsAg levels correlated with HDV viraemia in chronic HDV. (ii) Biochemical parameters did not accurately indicate the stage and grade of liver disease in chronic HDV and thus liver biopsy seems to remain the major tool for the evaluation of delta hepatitis patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19840253     DOI: 10.1111/j.1478-3231.2009.02140.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  22 in total

Review 1.  Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.

Authors:  Nicole D Ferrante; Vincent Lo Re
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.071

2.  Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics.

Authors:  Ingmar Mederacke; Birgit Bremer; Benjamin Heidrich; Janina Kirschner; Katja Deterding; Thomas Bock; Karsten Wursthorn; Michael P Manns; Heiner Wedemeyer
Journal:  J Clin Microbiol       Date:  2010-03-29       Impact factor: 5.948

3.  Noninvasive markers for staging fibrosis in chronic delta hepatitis.

Authors:  V Takyar; P Surana; D E Kleiner; K Wilkins; J H Hoofnagle; T J Liang; T Heller; C Koh
Journal:  Aliment Pharmacol Ther       Date:  2016-11-04       Impact factor: 8.171

4.  The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection.

Authors:  Elizabeth C Townsend; Grace Y Zhang; Rabab Ali; Marian Firke; Mi Sun Moon; Ma Ai Thanda Han; Benjamin Fram; Jeffrey S Glenn; David E Kleiner; Christopher Koh; Theo Heller
Journal:  J Gastroenterol Hepatol       Date:  2019-02-25       Impact factor: 4.029

5.  Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses.

Authors:  Teresa Pollicino; Giuseppina Raffa; Teresa Santantonio; Giovanni Battista Gaeta; Giuliano Iannello; Angela Alibrandi; Giovanni Squadrito; Irene Cacciola; Chiara Calvi; Giuseppe Colucci; Massimo Levrero; Giovanni Raimondo
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

6.  Long-term therapy of chronic delta hepatitis with peginterferon alfa.

Authors:  T Heller; Y Rotman; C Koh; S Clark; V Haynes-Williams; R Chang; R McBurney; P Schmid; J Albrecht; D E Kleiner; M G Ghany; T J Liang; J H Hoofnagle
Journal:  Aliment Pharmacol Ther       Date:  2014-05-11       Impact factor: 8.171

7.  Treatment options for hepatitis delta virus infection.

Authors:  Benjamin Heidrich; Michael P Manns; Heiner Wedemeyer
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

Review 8.  Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead.

Authors:  Heiner Wedemeyer; Michael P Manns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

Review 9.  Therapy of Delta Hepatitis.

Authors:  Cihan Yurdaydin; Ramazan Idilman
Journal:  Cold Spring Harb Perspect Med       Date:  2015-08-07       Impact factor: 6.915

Review 10.  HDV Pathogenesis: Unravelling Ariadne's Thread.

Authors:  Eirini D Tseligka; Sophie Clément; Francesco Negro
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.